Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026

Same author

Role of glymphatic system function in cognitive dysfunction among patients with bipolar disorder.

The international journal of neuropsychopharmacology·2026

Same author

Functional connectivity density as a biomarker for Alzheimer's disease: Distinct neural mechanisms in young- and late-onset subtypes.

Psychiatry and clinical neurosciences·2026

Same author

Assessing glymphatic function in schizophrenia and mood disorders: Insights from a diffusion tensor image along the perivascular space (DTI-ALPS) and neuroanatomical correlations.

Psychiatry and clinical neurosciences·2025

Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.

Neurology·2025

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Biomarkers.

Chiung-Chih Chang¹

¹Kaohsiung chang Gung Memorial Hospital, Kaohsiung, NA, Taiwan.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association

|December 25, 2025

Summary

A new global tau severity (gTS) score using Florzolotau (18F) PET reliably measures tau burden in progressive supranuclear palsy (PSP). This score correlates significantly with cognitive and motor impairments in PSP patients.

Area of Science:

Neurology
Nuclear Medicine
Neuroimaging

Background:

Florzolotau (18F) PET shows high specificity for diagnosing progressive supranuclear palsy (PSP).
Standardized quantification of global tau burden is essential for predicting PSP severity.
This study aimed to develop a global tau severity (gTS) score using Florzolotau (18F) PET.

Purpose of the Study:

Establish a global tau severity (gTS) score for Florzolotau (18F) PET in PSP.
Validate the gTS score's ability to reflect tau pathology and disease severity.
Assess the gTS score's correlation with cognitive and motor functions in PSP.

Main Methods:

Developed a PSP-specific tau mask and identified the optimal reference region for Florzolotau (18F) in a pilot cohort.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Determined the gTS score cutoff for group stratification in a validation cohort (n=116 PSP, n=94 controls).

Assessed correlations between the gTS score and cognitive (MMSE), motor (UPDRS), and disease severity (PSP Rating Scale) measures.

Main Results:

A gTS cutoff of 35.9 demonstrated high diagnostic performance (AUC=0.901, specificity=0.92, sensitivity=0.75).
The gTS score significantly correlated with cognitive function (MMSE, ρ=-0.26, p=0.005).
Significant correlations were found between gTS score and motor function (UPDRS, ρ=0.269, p=0.006) and overall disease severity (PSP Rating Scale, r=0.372, p<0.0001).

Conclusions:

The developed gTS score is a reliable metric for assessing tau burden in PSP.
The gTS score is significantly associated with cognitive and motor severity in PSP patients.
This standardized metric holds potential for clinical use in monitoring PSP progression and patient stratification.